Mark E Robson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3884281/publications.pdf

Version: 2024-02-01

273 papers	34,726 citations	4146 87 h-index	4015 176 g-index
281 all docs	281 docs citations	281 times ranked	34726 citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
2	Penetrance of male breast cancer susceptibility genes: a systematic review. Breast Cancer Research and Treatment, 2022, 191, 31-38.	2.5	10
3	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. Clinical Cancer Research, 2022, 28, 404-413.	7.0	13
4	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	2.5	7
5	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
6	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants. JAMA Oncology, 2022, 8, 587.	7.1	36
7	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. Npj Breast Cancer, 2022, 8, 37.	5.2	9
8	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
9	Cancer-Causative Mutations Occurring in Early Embryogenesis. Cancer Discovery, 2022, 12, 949-957.	9.4	21
10	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1450-1459.	2.5	10
11	Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. Annals of Surgical Oncology, 2022, 29, 4706-4713.	1.5	9
12	Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers. Annals of Surgical Oncology, 2022, 29, 5821-5825.	1.5	4
13	BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.. Journal of Clinical Oncology, 2022, 40, 5559-5559.	1.6	8
14	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	7.0	4
15	Tolerability of Breast Radiotherapy Among Carriers of ATM Germline Variants. JCO Precision Oncology, 2021, 5, 227-234.	3.0	5
16	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
17	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
18	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	3.0	10

#	Article	IF	Citations
19	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. The Cochrane Library, 2021, 2021, CD011395.	2.8	19
20	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecologic Oncology, 2021, 161, 521-526.	1.4	2
21	Longâ€term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. Cancer Medicine, 2021, 10, 5163-5174.	2.8	11
22	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. JCO Precision Oncology, 2021, 5, 1073-1081.	3.0	9
23	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. American Journal of Surgical Pathology, 2021, 45, 1274-1281.	3.7	6
24	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
25	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	9.4	79
26	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. Npj Breast Cancer, 2021, 7, 96.	5.2	38
27	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	6.3	6
28	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	2.4	29
29	Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2. Journal of Clinical Oncology, 2021, 39, 2528-2534.	1.6	11
30	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	6.3	66
31	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
32	Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19. JCO Oncology Practice, 2021, 17, e1278-e1285.	2.9	14
33	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135.	5.2	9
34	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	5.4	16
35	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	21.4	44
36	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenetics and Genomics, 2021, 31, 1-9.	1.5	0

#	Article	IF	Citations
37	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
38	Fumarate hydrataseFHc.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human Mutation, 2020, 41, 103-109.	2.5	25
39	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number â‰¥4.0 and <6.0. Archives of Pathology and Laboratory Medicine, 2020, 144, 597-601.	2.5	10
40	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
41	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. Journal of Thoracic Oncology, 2020, 15, 655-660.	1.1	25
42	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
43	The genomic landscape of metastatic histologic special types of invasive breast cancer. Npj Breast Cancer, 2020, 6, 53.	5.2	27
44	Yoga for Chemotherapy-Induced Peripheral Neuropathy and Fall Risk: A Randomized Controlled Trial. JNCI Cancer Spectrum, 2020, 4, pkaa048.	2.9	24
45	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
46	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Network Open, 2020, 3, e208501.	5.9	79
47	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
48	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
49	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	3.0	9
50	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	12.8	31
51	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <i>BRCA1/2</i> Genetic Risk Modifier Test. Public Health Genomics, 2020, 23, 6-19.	1.0	7
52	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232.	5.5	23
53	Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 1275-1279.	6.3	21
54	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	6.3	106

#	Article	IF	Citations
55	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
56	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of Clinical Oncology, 2020, 38, 1398-1408.	1.6	60
57	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. Journal of Clinical Oncology, 2020, 38, 2080-2106.	1.6	178
58	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
59	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	7.0	135
60	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight, 2020, 5, .	5.0	16
61	Broadening Criteria for BRCA1/2 Evaluation. JAMA - Journal of the American Medical Association, 2019, 322, 619.	7.4	9
62	Homologous recombination DNA repair defects in PALB2-associated breast cancers. Npj Breast Cancer, 2019, 5, 23.	5.2	39
63	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	27.8	295
64	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer, 2019, 120, 20-30.	2.8	75
65	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibilityâ€"Pandoraâ€™s Box Is Opening Wider. JAMA Oncology, 2019, 5, 1687.	7.1	13
66	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. European Radiology, 2019, 29, 3976-3985.	4.5	8
67	Differences between screen-detected and interval breast cancers among BRCA mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 141-148.	2.5	10
68	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianâ€™s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology, 2019, 30, 558-566.	1.2	493
69	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2019, 111, 522-523.	6.3	7
70	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum, 2019, 3, pkz027.	2.9	20
71	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
72	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Research and Treatment, 2019, 177, 61-66.	2.5	42

#	Article	IF	Citations
73	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. Journal of Medical Genetics, 2019, 56, 347-357.	3.2	32
74	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
75	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. BMJ Open, 2019, 9, e031092.	1.9	10
76	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
77	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	30.7	485
78	Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. JCO Precision Oncology, 2019, 3, 1-11.	3.0	19
79	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research, 2019, 25, 2717-2724.	7.0	102
80	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
81	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genomeâ€Wide Association Study: Functional Epistatic Interaction Between <scp>SLC</scp>38A7 and <scp>ALPPL</scp>2. Clinical Pharmacology and Therapeutics, 2019, 106, 219-227.	4.7	10
82	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
83	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	6.3	90
84	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genetics in Medicine, 2018, 20, 1324-1327.	2.4	31
85	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	6.3	170
86	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
87	Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. Breast Cancer Research and Treatment, 2018, 168, 543-550.	2.5	5
88	Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Womenâ€™s Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology, 2018, 36, 1513-1520.	1.6	44
89	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
90	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	3.5	148

#	Article	IF	Citations
91	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
92	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	7.1	132
93	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	21.4	411
94	A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. European Journal of Cancer, 2018, 101, 12-19.	2.8	72
95	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	1.2	33
96	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. Breast Cancer Research and Treatment, 2018, 172, 487-496.	2.5	29
97	A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer. Case Reports in Oncological Medicine, 2018, 2018, 1-5.	0.3	4
98	Moderate-Penetrance Predisposition to Breast Cancer. Current Breast Cancer Reports, 2018, 10, 232-239.	1.0	0
99	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. Journal of Clinical Oncology, 2018, 36, 1504-1504.	1.6	2
100	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2017, 162, 297-306.	2.5	16
101	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+Âbreast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Research and Treatment, 2017, 164, 189-199.	2.5	17
102	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
103	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. Journal of the National Cancer Institute, 2017, 109, .	6.3	28
104	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	5.2	108
105	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 2017, 377, 523-533.	27.0	2,256
106	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2017, 163, 565-571.	2.5	77
107	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
108	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. New England Journal of Medicine, 2017, 377, 1792-1793.	27.0	55

#	Article	IF	Citations
109	Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. European Journal of Radiology, 2017, 97, 37-43.	2.6	98
110	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
111	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
112	Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6708-6720.	7.0	194
113	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
114	Germline BRCA2 mutations detected in pediatric sequencing studies impact parentsâ€™ evaluation and care. Journal of Physical Education and Sports Management, 2017, 3, a001925.	1.2	17
115	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33.	1.5	111
116	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
117	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology, 2017, 13, 307-320.	2.4	41
118	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. Journal of Genetic Counseling, 2017, 26, 232-243.	1.6	14
119	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	242
120	The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. Annals of Internal Medicine, 2017, 167, 884.	3.9	2
121	Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. JCO Precision Oncology, 2017, 1, 1-10.	3.0	9
122	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. JCO Precision Oncology, 2017, 1, 1-13.	3.0	6
123	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	286
124	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263.	1.6	1
125	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
126	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189

#	Article	IF	Citations
127	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	27.0	1,205
128	Twentyâ€oneâ€“gene recurrence score assay in <scp>BRCA</scp>â€associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer, 2016, 122, 1178-1184.	4.1	42
129	Response: Table 1.. Journal of the National Cancer Institute, 2016, 108, djw173.	6.3	2
130	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
131	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	1.6	204
132	Genetic Testing Awareness and Attitudes among Latinos: Exploring Shared Perceptions and Gender-Based Differences. Public Health Genomics, 2016, 19, 34-46.	1.0	49
133	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	6.2	113
134	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
135	Population Frequency of Germline BRCA1/2 Mutations. Journal of Clinical Oncology, 2016, 34, 4183-4185.	1.6	107
136	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078.	1.6	147
137	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	9.4	41
138	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
139	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment, 2016, 160, 447-456.	2.5	16
140	Age- and Tumor Subtypeâ€“Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
141	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	27.6	258
142	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	7.1	270
143	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
144	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26

#	Article	IF	Citations
145	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	4.1	167
146	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
147	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
148	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257.	27.0	764
149	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids, 2015, 99, 32-38.	1.8	38
150	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
151	Inherited predisposition to endometrial cancer: Moving beyond Lynch syndrome. Cancer, 2015, 121, 644-647.	4.1	6
152	Oophorectomy for BRCA1 ER-negative diseaseâ€"an open debate. Nature Reviews Clinical Oncology, 2015, 12, 505-506.	27.6	3
153	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	1.6	603
154	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
155	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0
156	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
157	Understanding the Paradigm Challenges Posed by Multiplex Panel Testing for Cancer Susceptibility. Current Genetic Medicine Reports, 2014, 2, 250-254.	1.9	0
158	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
159	Multigene Panel Testing: Planning the Next Generation of Research Studies in Clinical Cancer Genetics. Journal of Clinical Oncology, 2014, 32, 1987-1989.	1.6	40
160	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
161	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 154-160.	2.4	91
162	Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698.	1.6	121

#	Article	IF	Citations
163	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. BMC Medicine, 2014, 12, 140.	5.5	36
164	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Research and Treatment, 2014, 145, 625-634.	2.5	11
165	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. Familial Cancer, 2014, 13, 459-467.	1.9	14
166	Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort. Journal of Thoracic Oncology, 2014, 9, 554-558.	1.1	63
167	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Research, 2013, 15, 402.	5.0	36
168	Revealing the Incidentalome When Targeting the Tumor Genome. JAMA - Journal of the American Medical Association, 2013, 310, 795.	7.4	60
169	Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report. European Journal of Cancer, 2013, 49, 2979-2985.	2.8	72
170	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
171	Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast Cancer Research and Treatment, 2013, 139, 497-506.	2.5	22
172	Impairment of BRCA1-Related DNA Double-Strand Break Repair Leads to Ovarian Aging in Mice and Humans. Science Translational Medicine, 2013, 5, 172ra21.	12.4	384
173	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast Cancer Research and Treatment, 2013, 138, 273-279.	2.5	31
174	Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2013, 20, 3469-3476.	1.5	125
175	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	3.5	105
176	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
177	Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies. PLoS Genetics, 2013, 9, e1003220.	3.5	44
178	Genetic Epidemiology of Breast Cancer. , 2013, , 1113-1125.		0
179	TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. Molecular Endocrinology, 2013, 27, 657-670.	3.7	49
180	Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?. Journal of Clinical Oncology, 2013, 31, 1267-1270.	1.6	217

#	Article	IF	Citations
181	Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	4.1	58
182	Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 2013, 8, e66961.	2.5	37
183	What Women with Breast Cancer Discuss with Clinicians About Risk for Their Adolescent Daughters. Journal of Psychosocial Oncology, 2012, 30, 484-502.	1.2	10
184	Risks to Relatives in Genomic Research: A Duty to Warn?. American Journal of Bioethics, 2012, 12, 12-14.	0.9	19
185	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
186	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. Journal of Clinical Oncology, 2012, 30, e229-e232.	1.6	9
187	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
188	Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping. Journal of Thoracic Oncology, 2012, 7, 1049-1052.	1.1	108
189	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. American Journal of Human Genetics, 2012, 91, 379-383.	6.2	21
190	Favorable prognosis in patients with T1a/T1bN0 tripleâ€negative breast cancers treated with multimodality therapy. Cancer, 2012, 118, 4944-4952.	4.1	64
191	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 2012, 133, 1125-1130.	2.5	144
192	GermlineBRCAmutation does not prevent response to taxaneâ€based therapy for the treatment of castrationâ€resistant prostate cancer. BJU International, 2012, 109, 713-719.	2.5	40
193	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 2012, 118, 493-499.	4.1	83
194	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	2.5	51
195	Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of Medical Genetics, 2011, 48, 523-525.	3.2	28
196	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	5.0	71
197	Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. Patient Education and Counseling, 2011, 83, 92-98.	2.2	74
198	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4224-4226.	1.6	23

#	Article	IF	Citations
199	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist, 2011, 16, 1397-1402.	3.7	227
200	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
201	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	7.0	28
202	Do Women Remain at Risk Even If They Do Not Inherit a Familial BRCA1/2 Mutation?. Journal of Clinical Oncology, 2011, 29, 4477-4478.	1.6	5
203	Should the Presence of Germline BRCA1/2 Mutations Influence Treatment Selection in Breast Cancer?. Journal of Clinical Oncology, 2011, 29, 3724-3726.	1.6	5
204	Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	44
205	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Research and Treatment, 2010, 123, 581-585.	2.5	15
206	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2010, 28, 893-901.	1.6	389
207	Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. Cancer Research, 2010, 70, 3278-3286.	0.9	63
208	Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 628-633.	1.6	43
209	New Pharmacogenomic Paradigm in Breast Cancer Treatment. Journal of Clinical Oncology, 2010, 28, 4665-4666.	1.6	14
210	Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer. Clinical Cancer Research, 2010, 16, 2115-2121.	7.0	263
211	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research, 2010, 16, 755-763.	7.0	82
212	Preface. Hematology/Oncology Clinics of North America, 2010, 24, xi-xii.	2.2	0
213	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 235-244.	13.7	1,584
214	Genome-wide Association Studies of Cancer Predisposition. Hematology/Oncology Clinics of North America, 2010, 24, 973-996.	2.2	34
215	Genome-Wide Association Studies of Cancer. Journal of Clinical Oncology, 2010, 28, 4255-4267.	1.6	159
216	Inherited Predisposition to Cancer: Introduction and Overview. Hematology/Oncology Clinics of North America, 2010, 24, 793-797.	2.2	7

#	Article	IF	Citations
217	Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma. PLoS ONE, 2010, 5, e10358.	2.5	90
218	The 6q22.33 Locus and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2468-2475.	2.5	22
219	BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2009, 27, 433-438.	1.6	194
220	American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment. Journal of Clinical Oncology, 2009, 27, 986-993.	1.6	55
221	Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers. Journal of the National Cancer Institute, 2009, 101, 205-209.	6.3	108
222	Functional redundancy of exon 12 ofBRCA2revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Human Mutation, 2009, 30, 1543-1550.	2.5	30
223	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Research and Treatment, 2009, 114, 127-135.	2.5	27
224	Inherited Predisposition to Gastrointestinal Stromal Tumor. Hematology/Oncology Clinics of North America, 2009, 23, 1-13.	2.2	44
225	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. Clinical Breast Cancer, 2008, 8, 418-424.	2.4	12
226	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology, 2008, 26, 1331-1337.	1.6	522
227	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1216-1222.	1.6	56
228	Is breast conservation a reasonable option for women with BRCA-associated breast cancer?. Nature Clinical Practice Oncology, 2007, 4, 10-11.	4.3	3
229	BRCA Mutations in Women with Ductal Carcinoma In situ. Clinical Cancer Research, 2007, 13, 4306-4310.	7.0	29
230	Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer. Clinical Cancer Research, 2007, 13, 223-227.	7.0	11
231	Management of an Inherited Predisposition to Breast Cancer. New England Journal of Medicine, 2007, 357, 154-162.	27.0	222
232	Adjuvant treatment recommendations in older women with breast cancerâ€"A survey of oncologists. Critical Reviews in Oncology/Hematology, 2007, 61, 255-260.	4.4	32
233	Protecting the privacy of third-party information: Recommendations for social and behavioral health researchers. Social Science and Medicine, 2007, 64, 213-222.	3.8	15
234	Treatment of Hereditary Breast Cancer. Seminars in Oncology, 2007, 34, 384-391.	2.2	12

#	Article	IF	Citations
235	Seizing the Opportunity: Recognition and Management of Hereditary Cancer Predisposition. Seminars in Oncology, 2007, 34, 367-368.	2.2	2
236	Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. Annals of Surgical Oncology, 2007, 14, 2510-2518.	1.5	82
237	A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy. Journal of the American Geriatrics Society, 2006, 54, 1119-1124.	2.6	86
238	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patientâ€™s perspective. Breast Cancer Research and Treatment, 2006, 98, 343-348.	2.5	85
239	Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2311-2313.	2.5	60
240	Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecologic Oncology, 2005, 96, 21-24.	1.4	35
241	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations inBRCA1 orBRCA2. Cancer, 2005, 103, 44-51.	4.1	132
242	Ovarian carcinoma screening in women at intermediate risk. Cancer, 2005, 104, 314-320.	4.1	23
243	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Liâ€“Fraumeni-like kindreds. Familial Cancer, 2005, 4, 177-181.	1.9	31
244	Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute, 2005, 97, 1382-1384.	6.3	80
245	A Comparison of Bilateral Breast Cancers in BRCA Carriers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1534-1538.	2.5	44
246	The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriersK.A. Metcalfe, H.T. Lynch, P. Ghadirian, N. Tung, I.A. Olivotto, W.D. Foulkes, E. Warner, O. Olopade, A. Eisen, B. Weber, et al. Gynecol Oncol 2005;96:222â€“26. Women's Oncology Review, 2005, 5, 163-164.	0.0	0
247	Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer. Clinical Cancer Research, 2004, 10, 5754-5761.	7.0	31
248	BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clinical Cancer Research, 2004, 10, 2918-2921.	7.0	156
249	Breast MRI for Women With Hereditary Cancer Risk. JAMA - Journal of the American Medical Association, 2004, 292, 1368.	7.4	45
250	Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia. Clinical Cancer Research, 2004, 10, 1250-1254.	7.0	97
251	Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. Cancer Research, 2004, 64, 5051-5053.	0.9	51
252	Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer, 2004, 3, 259-264.	1.9	36

#	Article	IF	Citations
253	Breast Cancer Surveillance in Women with Hereditary Risk Due to BRCA1 or BRCA2 Mutations. Clinical Breast Cancer, 2004, 5, 260-268.	2.4	27
254	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic Oncology, 2003, 89, 281-287.	1.4	130
255	Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecologic Oncology, 2003, 89, 440-446.	1.4	38
256	Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations. Cancer, 2003, 97, 1601-1608.	4.1	90
257	Ductal lavage in patients undergoing mastectomy for mammary carcinoma. Cancer, 2003, 98, 2170-2176.	4.1	44
258	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Medical Genetics, 2003, 4, 1.	2.1	106
259	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research, 2003, 6, R8-R17.	5.0	262
260	Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations. Journal of Clinical Oncology, 2003, 21, 4222-4227.	1.6	199
261	Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia. Journal of the National Cancer Institute, 2003, 95, 1548-1551.	6.3	183
262	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3752-3753.	1.6	20
263	Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2002, 94, 1773-1779.	6.3	318
264	Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation. New England Journal of Medicine, 2002, 346, 1609-1615.	27.0	1,363
265	Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer. Cancer Control, 2002, 9, 457-465.	1.8	38
266	Considerations in genetic counseling for inherited breast cancer predisposition. Seminars in Radiation Oncology, 2002, 12, 362-370.	2.2	0
267	Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene, 2002, 21, 7034-7041.	5.9	39
268	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genetics in Medicine, 2001, 3, 422-425.	2.4	17
269	Risk of Endometrial Carcinoma Associated with BRCA Mutation. Gynecologic Oncology, 2001, 80, 395-398.	1.4	147
270	Hereditary breast cancer. Current Problems in Surgery, 2001, 38, 387-480.	1.1	124

#	Article	IF	Citations
271	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens fromBRCA1 heterozygotes. Cancer, 2000, 89, 383-390.	4.1	97
272	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet, The, 2000, 356, 1876-1881.	13.7	538
273	Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer. The Cochrane Library, 0, , .	2.8	0